Defactinib, a highly selective FAK inhibitor was used to treat TGF-β (2 ng/ml) challenged lung fibroblast cells (IMR90) and DHLF-IPF cells in vitro. This evidence concerns the gene TGFB1 and idiopathic interstitial pneumonia.